Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.34 |
| ▸ | PDK3 | Q15120 | 5/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 5/20 | 0.34 |
| ▸ | OGG1 | O15527 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21199916 | 0.82 | GAA (0.40) | GAAALDH1A1S1PR2PDK1PDK2 | |
| SCHEMBL21200280 | 0.81 | S1PR2 (0.35) | MEN1CYP1A2CYP3A4CYP2C19KMT2A | |
| SCHEMBL31047260 | 0.75 | HSD11B1 (0.40) | — | |
| SCHEMBL21200192 | 0.74 | CNR2 (0.40) | MEN1CYP1A2CYP3A4KMT2ASMN1; SMN2 | |
| SCHEMBL21200585 | 0.68 | ALDH1A1 (0.51) | GAAMEN1CYP3A4CYP2C19KMT2A | |
| SCHEMBL31091996 | 0.67 | RXFP1 (0.52) | GAAMEN1CYP3A4CYP2C19KMT2A | |
| SCHEMBL29626593 | 0.67 | RXFP1 (0.52) | GAAMEN1CYP3A4CYP2C19KMT2A | |
| SCHEMBL28741906 | 0.67 | KDM4E (0.49) | MEN1CYP3A4KMT2AALDH1A1PDK1 | |
| SCHEMBL26624096 | 0.67 | S1PR2 (0.55) | S1PR2PDK1PDK2PDK3PDK4 | |
| SCHEMBL25379591 | 0.66 | GABRA2 (0.33) | S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | GAA 515/4885MEN1 4135/4885CYP1A2 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.